Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000547272 | SCV000628545 | benign | Neurofibromatosis, type 1 | 2025-02-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002314931 | SCV000663139 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2024-02-27 | criteria provided, single submitter | clinical testing | The p.M1260V variant (also known as c.3778A>G), located in coding exon 28 of the NF1 gene, results from an A to G substitution at nucleotide position 3778. The methionine at codon 1260 is replaced by valine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000547272 | SCV002560330 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002476108 | SCV002776694 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2024-02-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004722871 | SCV005331841 | uncertain significance | not provided | 2023-10-10 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 25486365, 22807134) |